Risk of non-hematologic cancer in individuals with high-count monoclonal B-cell lymphocytosis

B. M. Solomon, K. G. Chaffee, J. Moreira, S. M. Schwager, James R Cerhan, T. G. Call, Neil Elliot Kay, Susan L Slager, T. D. Shanafelt

Research output: Contribution to journalArticle

19 Scopus citations

Abstract

It is unknown whether individuals with monoclonal B-cell lymphocytosis (MBL) are at risk for adverse outcomes associated with chronic lymphocytic leukemia (CLL), such as the risk of non-hematologic cancer. We identified all locally residing individuals diagnosed with high-count MBL at Mayo Clinic between 1999 and 2009 and compared their rates of non-hematologic cancer with that of patients with CLL and two control cohorts: general medicine patients and patients who underwent clinical evaluation with flow cytometry but who had no hematologic malignancy. After excluding individuals with prior cancers, there were 107 high-count MBL cases, 132 CLL cases, 589 clinic controls and 482 flow cytometry controls. With 4.6 years median follow-up, 14 (13%) individuals with high-count MBL, 21 (4%) clinic controls (comparison MBL P

Original languageEnglish (US)
Pages (from-to)331-336
Number of pages6
JournalLeukemia
Volume30
Issue number2
DOIs
StatePublished - Feb 1 2016

    Fingerprint

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine

Cite this

Solomon, B. M., Chaffee, K. G., Moreira, J., Schwager, S. M., Cerhan, J. R., Call, T. G., Kay, N. E., Slager, S. L., & Shanafelt, T. D. (2016). Risk of non-hematologic cancer in individuals with high-count monoclonal B-cell lymphocytosis. Leukemia, 30(2), 331-336. https://doi.org/10.1038/leu.2015.235